I recently told you how the long-awaited revolution in the fight against cancer is here.

For the first time in more than 50 years, doctors have found a way to treat this dreadful disease — by using the capabilities of our own immune system.

This technology is called immunotherapy.

Some of the biggest pharmaceutical companies in the world are pouring tons of cash into this new treatment. And results show these companies are making amazing strides to prolong the lives of patients with some of the worst forms of cancer.

Immunotherapy is one of the biggest early-stage trends in the world. And I shared some of my favorite small-cap stocks that will benefit greatly from this trend.

Today, there is a new generation of immunotherapy. It’s not only curing deadly diseases like cancer — but also preventing patients from catching these diseases in the future.

This “new generation” technology has opened up another huge investment opportunity for investors.

Immunotherapy is one of the biggest trends in healthcare.

In short, this technology trains your body (immune system) to attack just the bad cells … not the good ones. That’s a big difference from current cancer treatments like radiation and chemotherapy, which kill all cells.

This new technology is being used to fight all kinds of diseases — including almost every form of cancer.

And recent test results from this new technology are nothing short of remarkable.

For example, melanoma and pancreatic cancers used to be viewed by doctors as a death sentence. Today, patients can live for years instead of months through different types of immunotherapy treatments.

For the first time in decades — there is now hope for people diagnosed with deadly cancers.

I’ve spent a lot of time researching this subject over the past two years. That’s because my dad passed away from cancer. Plus, my wife is a breast cancer survivor.

And over the past nine months, I’ve recommended several immunotherapy stocks to my subscribers. This includes the dominator in the field (Bristol-Myers) and several small-caps with unique technologies.

Here is how these picks have fared thus far …

The average percentage return from these five picks is 180.6%. And every position has generated positive returns since its recommended date.

I’m not posting these winners to brag. Like most investors, I’ve had my share of losers — including several within the biotech industry.

However, this illustrates how much money you can make by investing early in game-changing technologies.

For immunotherapy, it’s not too late for investors to make money.

This trend is still in its infancy. And as I explained before, there is new technology that’s helping patients with deadly diseases live even longer. This includes stimulating T-cells is ways never seen before. (T-cells are a type of white blood cell that destroys cancerous or infected cells.)

It’s almost like awakening an army inside your body to fight cancer. Not only is this army defeating cancer (by shrinking tumors) — but it’s also preventing these diseases from coming back in the future.

My advice is to start researching immunotherapy companies that have recently come to the market through Initial Public Offerings (IPOs).

This includes names like Aduro BioTech (ADRO) and Adaptimmune Therapeutics (ADAP).These are companies with new immunotherapy platforms.

I don’t suggest buying these stocks right away. They are extremely volatile — and just became public companies.

However, you may want to keep them on your watch list.

If we get an overall market pullback, it could create a great opportunity to get exposure to this secular game-changing trend.